Source Natural Foods & Herbal Supplements Ltd

On 24 Dec, Source Natural Foods & Herbal Supplements Ltd recorded a notable rise in its share price, advancing by 2.25% to close at ₹141.00. This movement reflects a short-term positive momentum despite the company’s challenging longer-term returns relative to broader market benchmarks.

Source Natural has demonstrated significant growth in net sales and profitability, with net sales increasing from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, and profit after tax rising from 2.12 Cr to 2.90 Cr during the same period. The company's total assets also grew from 21.45 Cr to 35.83 Cr, indicating a positive trend in financial performance.

Source Natural has shown significant growth in net sales, increasing from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, alongside rising profitability, with profit after tax growing from 2.12 Cr to 2.90 Cr during the same period, despite increased expenditures. Total assets also rose from 21.45 Cr to 35.83 Cr, indicating a strong overall financial performance.

Source Natural has shown significant growth in net sales and profitability, with net sales increasing from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, and profit after tax rising from 2.12 Cr to 2.90 Cr in the same period, reflecting strong financial performance and stability.

As of November 13, 2025, Source Natural is fairly valued with a PE ratio of 29.30 and a PEG ratio of 0.46, indicating reasonable valuation compared to peers, despite a 41.67% decline in stock performance over the past year.

Source Natural has shown significant growth in net sales, increasing from 19.77 crore in March 2023 to 44.92 crore in March 2025, with a profit after tax of 2.90 crore. The company has maintained a strong upward trend in profitability and total assets, despite fluctuations in profit margins.

The next results date for Source Natural is 14 November 2025.

As of 10-Nov, Source Natural Foods & Herbal Supplements Ltd is facing a decline in stock price to Rs 140.00, down 2.54%, and has underperformed its sector significantly. The stock is trading below all major moving averages and has seen a drastic drop in investor participation, with a year-to-date decline of 27.46% compared to the Sensex's rise of 6.91%.

As of November 7, 2025, Source Natural's valuation has shifted from attractive to fair, with a PE ratio of 29.64, a Price to Book Value of 4.14, and an EV to EBITDA ratio of 16.78, indicating moderate value compared to peers, despite a significant stock underperformance of -41.04% over the past year.

As of November 7, 2025, Source Natural is fairly valued with a PE ratio of 29.64, lower than some peers like Sun Pharma and Divi's Lab, but higher than Cipla, and has underperformed the Sensex with a return of -41.04% over the past year.

As of November 7, 2025, Source Natural is fairly valued with a PE ratio of 29.64, lower than some peers but higher than others, and has underperformed the Sensex by 41.04% over the past year, indicating potential for recovery despite not being a bargain.

As of October 31, 2025, Source Natural is considered undervalued with an attractive valuation grade, featuring a PE ratio of 29.87, an EV to EBITDA of 16.92, and a PEG ratio of 0.47, which are favorable compared to its peers, despite a year-to-date return of -24.97% against the Sensex's 7.42%.